Zobrazeno 1 - 10
of 321
pro vyhledávání: '"MENINGOCOCCAL B"'
Autor:
Adriana Efron, Alessia Biolchi, Cecilia Sorhouet Pereira, Sara Tomei, Josefina Campos, Denise De Belder, María Alicia Moscoloni, Mauricio Santos, Gabriela Vidal, Florencia Nocita, Carla Vizzotti, Mariagrazia Pizza
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 3 (2023)
ABSTRACTInvasive meningococcal disease (IMD) is a life-threatening disease caused by meningococcal serogroups A, B, C, W, X, and Y, of which B and W are most common in Argentina. The 4-component meningococcal serogroup B (4CMenB) vaccine contains thr
Externí odkaz:
https://doaj.org/article/c66b3266ecfb48d0875e728f67f19c46
Autor:
Maria Stella, Maria Giuliani, Alessia Biolchi, Sara Tomei, Rosita De Paola, Xilian Bai, Ray Borrow, Jay Lucidarme, Rita La Gaetana, Daniela Toneatto, Mariagrazia Pizza, Laura Serino, Elena Mori, Marzia Monica Giuliani
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 4, Pp 945-948 (2020)
The Meningococcal Antigen Typing System (MATS) has been developed as an hSBA surrogate to evaluate potential coverage afforded by the 4-component meningococcal serogroup B vaccine (4CMenB: Bexsero, GSK). We investigated whether the lower value of MAT
Externí odkaz:
https://doaj.org/article/e53e242923ad4b62bcc1fc78c53c7834
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 1 (2022)
This study aimed to determine social and behavioral predictors of completing a course of 4CMenB vaccine in adolescents in a parallel cluster randomized controlled trial enrolling secondary school students (approximately 15–18 years of age) in South
Externí odkaz:
https://doaj.org/article/9016dc27dd15438cbd295c4c06422fd9
Publikováno v:
Infection and Drug Resistance, Vol Volume 12, Pp 3169-3188 (2019)
Irene Rivero-Calle,1,2 Peter Francis Raguindin,2 Jose Gómez-Rial,2 Carmen Rodriguez-Tenreiro,2 Federico Martinón-Torres1,2 1Translational Pediatrics and Infectious Diseases, Department of Pediatrics, Hospital Clínico Universitario de Santiago de C
Externí odkaz:
https://doaj.org/article/2d73e8fb0b8a483aac342532e5b686c5
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 8, Pp 2075-2081 (2018)
When the meningococcus B vaccine was introduced into Italy in 2017, it was recommended for newborns based on national epidemiological data indicating that they were at greater risk. However, the vaccination service of the local health authority of L'
Externí odkaz:
https://doaj.org/article/a3fdfd29706e4b80a6891361876b2aef
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alies van Lier, José A. Ferreira, Liesbeth Mollema, Elisabeth A. M. Sanders, Hester E. de Melker
Publikováno v:
BMC Research Notes, Vol 10, Iss 1, Pp 1-6 (2017)
Abstract Objective For the decision-making process regarding introduction of new vaccines into the National Immunisation Programme (NIP), advance insight into the potential acceptance among the population is relevant. We studied the intention of pare
Externí odkaz:
https://doaj.org/article/32ef3a081201465ea53347b0b1568cd4
Autor:
Julian Wolfson, Angela K. Ulrich, Sara Lammert, Jonathan Pletcher, Shannon B. McKearnan, Nicole E. Basta, M. Elizabeth Halloran
Publikováno v:
J Am Coll Health
After an outbreak of meningococcal B (MenB) disease at a university, we surveyed students regarding their vaccination status 2 months and 20 months after campus-led vaccination campaigns and compared students’ self-report to vaccination records. Ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4b9a539751d3f2c4e07aa10a722a6b6
https://pubmed.ncbi.nlm.nih.gov/32672510
https://pubmed.ncbi.nlm.nih.gov/32672510
Autor:
Stephen Clark, Ann Holland, Aiswarya Lekshmi, Shamez N Ladhani, Rosita De Paola, Mary Ramsay, Jay Lucidarme, Laura Serino, Jennifer Louth, Helen Campbell, Laura Willerton, Xilian Bai, Sonia Ribeiro, Ray Borrow
Publikováno v:
Journal of Infection. 84:136-144
OBJECTIVES: In 2015 the UK became the first country to implement the meningococcal B (MenB) vaccine, 4CMenB, into the national infant program. 4CMenB is expected to cover meningococci expressing sufficient levels of cross-reactive proteins. This stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29bb5a478930fa23f7ad53085b4a07af
https://doi.org/10.1016/j.jinf.2021.11.015
https://doi.org/10.1016/j.jinf.2021.11.015
Autor:
Sara Boccalini, Beatrice Zanella, Paolo Landa, Daniela Amicizia, Angela Bechini, Maddalena Innocenti, Mariasilvia Iovine, Elvina Lecini, Francesca Marchini, Diana Paolini, Gino Sartor, Francesca Zangrillo, Piero Luigi Lai, Paolo Bonanni, Donatella Panatto
Publikováno v:
Microorganisms, Vol 8, Iss 11, p 1681 (2020)
Although meningococcal disease has a low incidence in Italy, it is a public health concern owing to its high lethality rate and high frequency of transitory and/or permanent sequelae among survivors. The highest incidence rates are recorded in infant
Externí odkaz:
https://doaj.org/article/5b8758bb51a64a96aa47d0dd3a4b3fc3